Health News

Dyax Corp. announced today that results from EDEMA3, the Company’s first Phase 3 trial evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema, were published in the August issue of The New England Journal of Medicine. KALBITOR, discovered and developed by Dyax, is available in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

Read more

Filed under: Pharmacy News
Tags: medicine, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Zoologists search sea for drugs of the future (0)
  No matter how sophisticated modern medicine becomes, common ailments like fungal infections can outrun the best of the world's antibiotics. Read more [tags] Pharmacy News [/tags]
  
  
• Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark (0)
  Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark. Read more [tags] Pharmacy News [/tags]
  
  
• Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK (0)
  Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of [...]
  
  
• Zocor, Crestor drugs may cause serious muscle and kidney problems (0)
  Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. Read more [tags] Pharmacy News [/tags]